% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • frogsleapmerlot frogsleapmerlot Mar 21, 2004 5:33 PM Flag


    This is a stock that will trade @50 to 60 times earnings, so a $120M to the bottom line will do just that. Thats about a $6 Billion market cap on $500M in sales after 50/50 split on a $1 Billion in sales projected by FY2007. Projections on the seize of the insomnia market is $5 Billion by FY2010. So IMO Indiplon could have sales in the $2 Billion range by FY2010.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Keep in mind, NBIX is a 1-trick pony biotech for the forseeable future. The number of BTs with 1 product that can carry a 60 multiple are limited, the reason being the discount the street needs to afford a company with that kind of business risk. Even with PFE as a partner, the chances of Indiplon ramping to 1B in sales in 3 years with Estorra, Ambien MR and generic Ambien on the market is at best a stretch.

48.77+0.70(+1.46%)May 24 4:00 PMEDT